Iproniazid Phosphate
Iproniazid Phosphate a monoamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant. It was originally intended to treat tuberculosis when it was discovered that patients given iproniazid became "inappropriately happy," subsequently with further research iproniazid was marketed specifically for depression in 1958. It was later replaced by less hepatotoxic drugs.
Primary Characteristics
It is of Synthetic origin and belongs to hydrazine.
Molecular Weight: 277.2 · Non-proprietary name: Iproniazid Phosphate.
Pharmacokinetics
None recorded.
Advertisement
Indications
Iproniazid Phosphate is primarily indicated in conditions like Depression.
Contraindications
None recorded.
Dosage
Iproniazid Phosphate's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 100 mg | 100 mg | — | oral | |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Iproniazid Phosphate in overdosage may give rise to further complications which include Hepatitis .
The signs and symptoms that are produced after acute overdosage of Iproniazid Phosphate are Convulsions , Porphyria, Delirium, Orthostatic hypotension, Euphoria .
Iproniazid Phosphate is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Drowsiness, Dry mouth, Fatigue, Headache, Insomnia, Nausea and vomiting, Weakness.
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.24.2.1 — Drugs used in depression